H
Howard L. Kaufman
Researcher at Harvard University
Publications - 349
Citations - 22590
Howard L. Kaufman is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Immunotherapy. The author has an hindex of 64, co-authored 328 publications receiving 18169 citations. Previous affiliations of Howard L. Kaufman include Albert Einstein College of Medicine & Rush University.
Papers
More filters
Journal ArticleDOI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka,Howard L. Kaufman,Frances A. Collichio,Thomas Amatruda,Neil Senzer,Jason Chesney,Keith A. Delman,Lynn E. Spitler,Igor Puzanov,Sanjiv S. Agarwala,Mohammed M. Milhem,Lee D. Cranmer,Brendan D. Curti,Karl D. Lewis,Merrick I. Ross,Troy H. Guthrie,Gerald P. Linette,Gregory A. Daniels,Kevin J. Harrington,Mark R. Middleton,Wilson H. Miller,Jonathan S. Zager,Yining Ye,Bin Yao,Ai Li,Susan Doleman,Ari M. Vanderwalde,Jennifer Gansert,Robert Coffin +28 more
TL;DR: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma.
Journal ArticleDOI
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov,Adi Diab,K. Abdallah,Clifton O. Bingham,C. Brogdon,Ramona Dadu,Lamya Hamad,Sang Taek Kim,Mario E. Lacouture,Nicole R. LeBoeuf,D. Lenihan,C. Onofrei,Vickie R. Shannon,Rajeev Sharma,Ann W. Silk,Dimitra Skondra,Maria E. Suarez-Almazor,Yinghong Wang,K. Wiley,Howard L. Kaufman,Marc S. Ernstoff +20 more
TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Journal ArticleDOI
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman,Jeffery S. Russell,Omid Hamid,Shailender Bhatia,Patrick Terheyden,Sandra P. D'Angelo,Kent C. Shih,Céleste Lebbé,Gerald P. Linette,Michele Milella,Isaac Brownell,Karl D. Lewis,Jochen H. Lorch,Kevin M. Chin,Lisa Mahnke,Anja von Heydebreck,Jean Marie Cuillerot,Paul Nghiem +17 more
TL;DR: Treatment with avelumab was associated with durable responses, most of which are still ongoing, and was well tolerated; hence, a Velumab represents a new therapeutic option for advanced Merkel cell carcinoma.
Journal ArticleDOI
Oncolytic viruses: a new class of immunotherapy drugs
TL;DR: This Review provides a comprehensive overview of the basic biology supporting oncolytic viruses as cancer therapeutic agents, describes oncoleytic viruses in advanced clinical trials and discusses the unique challenges in the development of on colytic virus as a new class of drugs for the treatment of cancer.
Journal ArticleDOI
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J. Schwartzentruber,David H. Lawson,Jon M. Richards,Robert M. Conry,Donald M. Miller,Jonathan S. Treisman,Fawaz Gailani,Lee B. Riley,Kevin C. Conlon,Barbara A. Pockaj,Kari Kendra,Richard L. White,Rene Gonzalez,Timothy M. Kuzel,Brendan D. Curti,Phillip D. Leming,Eric D. Whitman,Jai Balkissoon,Douglas S. Reintgen,Howard L. Kaufman,Francesco M. Marincola,Maria J. Merino,Steven A. Rosenberg,Peter L. Choyke,Don Vena,Patrick Hwu +25 more
TL;DR: In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine andInterleukin-2 than with interleuk in-2 alone.